chondroitin-sulfates and beta-glycerophosphoric-acid

A monoclonal anti-chondroitin sulfate antibody (CS-56) that recognizes native chondroitin sulfate glycosaminoglycans (CSGAG) was used to quantify changes in CSGAG labeling levels in mineralizing human fetal osteoblast-like cell multilayers up to 40 days postconfluence. In control cultures, mean labeling of CSGAG increased in nonmineralized areas from around eight gold probes per micron 2 (gpm) at 20 days to 26 gpm at 40 days. Labeling was markedly increased in the mineralized tissue, to 560 gpm at 30 days and 580 gpm at 40 days. In beta-glycerophosphate-treated cultures, the mineralized areas were increased and appeared earlier (20 days) than in the control cultures. In these cultures, mean CSGASG labeling increased in nonmineralized areas from around 5 gpm at 20 days to 26 gpm at 30 days and was further increased in mineralized areas to 270 gpm at 20 days and 298 gpm at 30 days. Mineralization was not noted in cultures treated with 10(-8) M 1,25-dihydroxyvitamin D, and CSGAG labeling remained low (< 5 gpm) during the study period. These results indicate that an increase in immunoreactive CSGAG is associated with mineralization in this culture system. One possible interpretation of these findings is that proteoglycan molecules or at least their CSGAG side chains may be involved in the mineralization process.

Topics: Antibodies, Monoclonal; Calcification, Physiologic; Calcitriol; Cells, Cultured; Chondroitin Sulfates; Fetus; Glycerophosphates; Glycosaminoglycans; Humans; Immunohistochemistry; Microscopy, Electron; Osteoblasts